Myocardial infarction and heart failure in the db/db diabetic mouse

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 1, 2006, Pages

  Greer, James J M ^a   Ware, Derek P ^b   Lefer, David J ^a,c  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Contractility; Diabetes mellitus; Hypertrophy; Ischemia; Left ventricular dimension; Reperfusion

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; GLYCOSYLATED HEMOGLOBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SIZE; HEMOGLOBIN BLOOD LEVEL; IN VIVO STUDY; INSULIN BLOOD LEVEL; LUNG EDEMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ANIMAL; BLOOD; CARDIOMEGALY; CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; REPERFUSION INJURY;

ANIMALS; BLOOD GLUCOSE; CARDIOMEGALY; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART FAILURE, CONGESTIVE; HEMOGLOBIN A, GLYCOSYLATED; INSULIN; MICE; MICE, OBESE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PULMONARY EDEMA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33644813721     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00583.2005     Document Type: Article

References (42)

1. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, and Larsen TS. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-α activator. Am J Physiol Heart Circ Physiol 283: H949-H957, 2002.
2. Aasum E, Hafstad AD, Severson DL, and Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52: 434-441, 2003.
3. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625, 2005.
5. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11: 1278-1289, 2003.
6. Calver A, Collier J, and Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 90: 2548-2554, 1992.
7. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, and Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495, 1996.
8. Clark CM Jr. and Perry RC. Type 2 diabetes and macrovascular disease: epidemiology and etiology. Am Heart J 138: S330-S333, 1999.
9. Cohen RA. Pathways controlling healthy and diseased arterial smooth muscle. Am J Cardiol 72: 39C-46C, 1993.
10. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E, and Bauters C. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25: 656-662, 2004.
11. Flaherty JT and Weisfeldt ML. Reperfusion injury. Free Radic Biol Med 5: 409-419, 1988.
12. Garcia MJ, McNamara PM, Gordon T, and Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23: 105-111, 1974.
13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, and Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
14. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, and Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14-E22, 2001.
15. Ichinose F, Bloch KD, Wu JC, Hataishi R, Aretz HT, Picard MH, and Scherrer-Crosbie M. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 286: H1070-H1075, 2004.
16. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Van de Werf F, Collen D, and Bloch KD. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 94: 1256-1262, 2004.
17. Jones SP, Girod WG, Granger DN, Palazzo AJ, and Lefer DJ. Reperfusion injury is not affected by blockade of P-selectin in the diabetic mouse heart. Am J Physiol Heart Circ Physiol 277: H763-H769, 1999.
18. Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R, and Lefer DJ. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA 100: 4891-4896, 2003.
19. Jones SP, Greer JJ, Ware PD, Yang J, Walsh K, and Lefer DJ. Deficiency of iNOS does not attenuate severe congestive heart failure in mice. Am J Physiol Heart Circ Physiol 288: H365-H370, 2005.
20. Jones SP, Trocha SD, and Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 21: 2059-2064, 2001.
21. Kannel WB, Hjortland M, and Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34: 29-34, 1974.
22. Kannel WB and McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035-2038, 1979.
23. Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, and Kersten JR. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 96: 183-188, 2002.
24. Koltai MZ, Hadhazy P, Posa I, Kocsis E, Winkler G, Rosen P, and Pogatsa G. Characteristics of coronary endothelial dysfunction in experimental diabetes. Cardiovasc Res 34: 157-163, 1997.
25. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, and Pouleur H. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 88: 2277-2283, 1993.
26. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Fuchs M, Hornig B, Haller H, and Drexler H. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1933-1939, 2004.
27. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, Gibson MF, and Lefer AM. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 15: 1454-1456, 2001.
28. Makimattila S and Yki-Jarvinen H. Endothelial dysfunction in human diabetes. Curr Diab Rep 2: 26-36, 2002.
29. Meigs JB, Hu FB, Rifai N, and Manson JE. Biomarkers of endothelial dysfunction and risk of Type 2 diabetes mellitus. JAMA 291: 1978-1986, 2004.
30. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, and Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21: 69-75, 1998.
31. Panes J, Kurose I, Rodriguez-Vaca D, Anderson DC, Miyasaka M, Tso P, and Granger DN. Diabetes exacerbates inflammatory responses to ischemia-reperfusion. Circulation 93: 161-167, 1996.
32. Paulson DJ. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 34: 104-112, 1997.
33. Remme WJ. Congestive heart failure-pathophysiology and medical treatment. J Cardiovasc Pharmacol 8, Suppl 1: S36-S52, 1986.
34. Salas A, Panes J, Elizalde JI, Casadevall M, Anderson DC, Granger DN, and Pique JM. Mechanisms responsible for enhanced inflammatory response to ischemia-reperfusion in diabetes. Am J Physiol Heart Circ Physiol 275: H1773-H1781, 1998.
35. Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, and Lewis SM. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 62: 665-669, 1988.
36. Semeniuk LM, Kryski AJ, and Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 283: H976-H982, 2002.
37. Son SM, Whalin MK, Harrison DG, Taylor WR, and Griendling KK. Oxidative stress and diabetic vascular complications. Curr Diab Rep 4: 247-252, 2004.
38. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, and Zile MR. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85: 364-376, 1999.
39. Tanaka K, Kehl F, Gu W, Krolikowski JG, Pagel PS, Warltier DC, and Kersten JR. Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 282: H2018-H2023, 2002.
40. Tesfamariam B and Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol Heart Circ Physiol 263: H321-H326, 1992.
41. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, and Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88: 1291-1298, 2001.
42. Weihrauch D, Lohr NL, Mraovic B, Ludwig LM, Chilian WM, Pagel PS, Warltier DC, and Kersten JR. Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin. Circulation 109: 2343-2348, 2004.